Valby, Denmark

Pekka Kallunki

USPTO Granted Patents = 18 

 

Average Co-Inventor Count = 5.6

ph-index = 8

Forward Citations = 106(Granted Patents)


Company Filing History:


Years Active: 2019-2025

Loading Chart...
Loading Chart...
18 patents (USPTO):Explore Patents

Title: Pekka Kallunki: Innovator in Synucleinopathy Treatment

Introduction

Pekka Kallunki is a prominent inventor based in Valby, Denmark. He has made significant contributions to the field of medical research, particularly in the treatment of synucleinopathies. With a total of 18 patents to his name, Kallunki's work focuses on innovative therapeutic approaches for neurodegenerative diseases.

Latest Patents

Kallunki's latest patents include groundbreaking inventions aimed at treating synucleinopathies. One notable patent is titled "Agents, uses and methods for the treatment of synucleinopathy." This invention relates to a combinational treatment using a monoclonal anti-alpha-synuclein antibody alongside an additional medicament. The antibodies developed can be utilized for treating various forms of synucleinopathy, including Parkinson's disease, Diffuse Lewy Body Disease, and multiple system atrophy. Another significant patent is "Compositions and methods for treating synucleinopathies." This invention describes stable and low viscosity liquid pharmaceutical compositions that comprise antibodies binding to human alpha synuclein. These compositions are designed for effective treatment of synucleinopathies or prodromal synucleinopathy.

Career Highlights

Kallunki is currently associated with H. Lundbeck A/S, a leading pharmaceutical company specializing in brain diseases. His work at Lundbeck has allowed him to focus on developing innovative treatments that address critical health challenges related to neurodegenerative disorders.

Collaborations

Throughout his career, Kallunki has collaborated with talented professionals in the field. Notable coworkers include Karina Fog and Louise Buur Vesterager, who have contributed to the advancement of research and development in synucleinopathy treatments.

Conclusion

Pekka Kallunki's contributions to the field of synucleinopathy treatment through his innovative patents and collaborations highlight his commitment to improving patient outcomes. His work continues to pave the way for advancements in the understanding and treatment of neurodegenerative diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…